| Code | CSB-RA004936MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to CDX-1140, targeting CD40, a critical costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. CD40 is expressed on antigen-presenting cells, including dendritic cells, B cells, and macrophages, where it plays a pivotal role in regulating adaptive immune responses and bridging innate and adaptive immunity. Upon binding with its ligand CD40L, CD40 activates downstream signaling pathways that enhance T cell priming, promote cytokine production, and stimulate antibody class switching. Dysregulation of CD40 signaling is implicated in various pathological conditions, including autoimmune diseases, inflammatory disorders, and cancer, where its immunostimulatory properties have garnered significant interest for therapeutic intervention.
CDX-1140 is an agonistic antibody that selectively activates CD40 signaling to enhance anti-tumor immune responses, currently under investigation in clinical trials for solid tumors and hematologic malignancies. This biosimilar provides researchers with a valuable tool for investigating CD40-mediated immune activation, exploring cancer immunotherapy mechanisms, and studying the receptor's role in immune regulation and disease pathogenesis.
There are currently no reviews for this product.